Compare · FMS vs VMD
FMS vs VMD
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Viemed Healthcare Inc. (VMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and VMD operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 37.9x VMD ($346.6M).
- Over the past year, FMS is down 7.8% and VMD is up 29.1% - VMD leads by 36.9 points.
- VMD has been more active in the news (10 items in the past 4 weeks vs 7 for FMS).
- FMS has more recent analyst coverage (23 ratings vs 2 for VMD).
- Company
- Fresenius Medical Care AG
- Viemed Healthcare Inc.
- Price
- $23.50-0.04%
- $9.10+0.00%
- Market cap
- $13.13B
- $346.6M
- 1M return
- -5.62%
- -24.95%
- 1Y return
- -7.83%
- +29.08%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 10
- Recent ratings
- 23
- 2
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Viemed Healthcare Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target
Latest VMD
- Barrington Research initiated coverage on Viemed Healthcare with a new price target
- Viemed Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Heltz Sabrina converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 22% to 82,520 units (SEC Form 4)
- Director Dobbs Randy E. converted options into 20,954 shares and returned $37,468 worth of shares to the company (4,191 units at $8.94), increasing direct ownership by 13% to 142,253 units (SEC Form 4)
- Director Kaushal Nitin converted options into 18,786 shares, increasing direct ownership by 13% to 161,361 units (SEC Form 4)
- Director Smokoff Timothy converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 20% to 90,547 units (SEC Form 4)
- SEC Form S-8 filed by Viemed Healthcare Inc.
- SEC Form 10-Q filed by Viemed Healthcare Inc.
- Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viemed Healthcare Announces Second Quarter 2026 Financial Results